| United States | Japan | ||
---|---|---|---|---|
Child group (n = 98,973) | Adolescent group (n = 62,002) | Child group (n = 4595) | Adolescent group (n = 1508) | |
Therapy on OROS-MPH index date, n (%) | ||||
 Monotherapy | 95,755 (96.7) | 60,029 (96.8) | 4235 (92.2) | 1358 (90.1) |
 Combination therapya | 3218 (3.3) | 1973 (3.2) | 360 (7.8) | 150 (9.9) |
Initial daily dose, mg/day | ||||
 Median initial dose (IQR) | 18 (18–36) | 36 (18–45) | 18 (18–18) | 18 (18–18) |
 18, n (%) | 51,985 (52.5) | 18,030 (29.1) | 4223 (91.9) | 1174 (77.9) |
 27, n (%) | 15,784 (15.9) | 8577 (13.8) | 79 (1.7) | 84 (5.6) |
 36, n (%) | 18,869 (19.1) | 19,227 (31.0) | 84 (1.8) | 86 (5.7) |
 45, n (%) | 1157 (1.2) | 1006 (1.6) | 167(3.6) | 100 (6.6) |
 54, n (%) | 8262 (8.3) | 11,918 (19.2) | 7 (0.2) | 7 (0.5) |
  > 54, n (%) | 2916 (2.9) | 3244 (5.2) | 35 (0.8) | 57 (3.8) |
Maintenance daily doseb, mg/day | ||||
 N (%) | 75,201 (76.0) | 41,937 (67.6) | 3433 (74.7) | 961 (63.7) |
 Median maintenance dose (IQR) | 36 (18–36) | 36 (27–54) | 18 (18–27) | 27 (18–27) |
 18, n (%) | 19,193 (25.5) | 5721 (13.6) | 2053 (59.8) | 404 (42.0) |
 27, n (%) | 16,138 (21.5) | 6132 (14.6) | 1013 (29.5) | 367 (38.2) |
 36, n (%) | 24,397 (32.4) | 17,150 (40.9) | 221 (6.4) | 107 (11.1) |
 45, n (%) | 591 (0.8) | 350 (0.8) | 84 (2.4) | 67 (7.0) |
 54, n (%) | 12,646 (16.8) | 11,900 (28.4) | 47 (1.4) | 13 (1.4) |
  > 54, n (%) | 2236 (3.0) | 684 (1.6) | 15 (0.4) | 3 (0.3) |
Maximum daily dose, mg/day | ||||
 Median maximum dose (IQR) | 36 (27–54) | 36 (36–54) | 27 (18–36) | 27 (18–45) |
 18, n (%) | 20,621 (20.8) | 7522 (12.1) | 2013 (43.8) | 470 (31.2) |
 27, n (%) | 17,548 (17.7) | 7209 (11.6) | 1278 (27.8) | 403 (26.7) |
 36, n (%) | 27,284 (27.6) | 18,776 (30.3) | 321 (7.0) | 181 (12.0) |
 45, n (%) | 1499 (1.5) | 623 (1.0) | 702 (15.3) | 224 (14.9) |
 54, n (%) | 24,319 (24.6) | 20,377 (32.9) | 70 (1.5) | 55 (3.6) |
  > 54, n (%) | 7702 (7.8) | 7495 (12.1) | 211 (4.6) | 175 (11.6) |
Average daily dose, mg/day | ||||
 Median average daily dose (IQR) | 30 (21–38) | 36 (27–48) | 20 (18–26) | 24 (18–32) |
  < 19, n (%) | 21,152 (21.4) | 7610 (12.3) | 2146 (46.7) | 497 (33.0) |
 19–27, n (%) | 25,159 (25.4) | 9897 (16.0) | 1712 (37.3) | 524 (34.7 |
 28–36, n (%) | 26,181 (26.5) | 19,014 (30.7) | 506 (11.0) | 253 (16.8) |
 37–45, n (%) | 12,011 (12.1) | 8526 (13.8) | 145 (3.2) | 128 (8.5) |
 46–54, n (%) | 10,994 (11.1) | 12,965 (20.9) | 47 (1.0) | 58 (3.8) |
  > 54, n (%) | 3476 (3.5) | 3990 (6.4) | 39 (0.8) | 48 (3.2) |
Duration of the index episode, months | ||||
 Median duration (IQR) | 9.6 (2.3–21.4) | 6.4 (1.8–15.9) | 14.7 (2.3–29.8) | 9.1 (1.6–20.6) |
  < 6 months, n (%) | 39,638 (40.0) | 30,073 (48.5) | 1617 (35.2) | 651 (43.2) |
 6–12 month, n (%) | 14,335 (14.5) | 10,398 (16.8) | 348 (7.6) | 168 (11.1) |
  > 12 months, n (%) | 45,000 (45.5) | 21,531 (34.7) | 2630 (57.2) | 689 (45.7) |
Number of prescriptions within this episode, n (%) | ||||
 1 | 20,006 (20.2) | 15,275 (24.6) | 830 (18.1) | 271 (18.0) |
 2–3 | 16,182 (16.3) | 14,273 (23.0) | 504 (11.0) | 239 (15.8) |
 4–9 | 25,870 (26.1) | 18,012 (29.1) | 739 (16.1) | 333 (22.1) |
 10–20 | 22,289 (22.5) | 10,208 (16.5) | 1103 (24.0) | 344 (22.8) |
  > 20 | 14,626 (14.8) | 4234 (6.8) | 1419 (30.9) | 321 (21.3) |